secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001654954-24-014547
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M
--------------------------------------------------------------------------------

- Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).
- Operating expenses fell 52% to $1.5M on $3.1M in annualized cost savings from restructuring.
- Cash and cash equivalents were $4.7M as of September 30, 2024.
- Accelerated enrollment in global pilot study for TAEUS liver fat assessment; activated site at LMU Germany.
- Added AI/ML/DL features to TAEUS; IP portfolio expanded to 82 issued patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/0001654954-24-014547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer